Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children.

Canh DG, Lin FY, Thiem VD, Trach DD, Trong ND, Mao ND, Hunt S, Schneerson R, Robbins JB, Chu C, Shiloach J, Bryla DA, Bonnet MC, Schulz D, Szu SC.

Infect Immun. 2004 Nov;72(11):6586-8.

2.

Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.

Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, Bryla DA, Chu C, Schiloach J, Robbins JB, Schneerson R, Szu SC.

N Engl J Med. 2003 Oct 2;349(14):1390-1. No abstract available.

PMID:
14523155
3.

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.

Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, Schneerson R, Szu SC.

N Engl J Med. 2001 Apr 26;344(17):1263-9.

4.

Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.

Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, Farzan N, Shiloach J, Bryla DA, Majadly F, Roberson R, Robbins JB, Schneerson R.

Infect Immun. 2001 Mar;69(3):1351-7.

6.

Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.

Taranger J, Trollfors B, Lagergård T, Sundh V, Bryla DA, Schneerson R, Robbins JB.

J Infect Dis. 2000 Mar;181(3):1010-3.

PMID:
10720524
7.

Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Konadu EY, Lin FY, Hó VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas AB, Li J, Bryla DA, Robbins JB, Szu SC.

Infect Immun. 2000 Mar;68(3):1529-34.

8.

Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, Bryla DA, Schneerson R, Robbins JB, Szu SC.

Infect Immun. 1999 Nov;67(11):5806-10.

9.

Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice.

Pavliakova D, Chu C, Bystricky S, Tolson NW, Shiloach J, Kaufman JB, Bryla DA, Robbins JB, Schneerson R.

Infect Immun. 1999 Oct;67(10):5526-9.

10.

Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.

Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, Robbins JB, Schneerson R.

J Infect Dis. 1999 Jun;179(6):1565-8.

PMID:
10228084
11.

Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.

Trollfors B, Taranger J, Lagergård T, Sundh V, Bryla DA, Schneerson R, Robbins JB.

Clin Infect Dis. 1999 Mar;28(3):552-9.

PMID:
10194077
12.

Immunity to pertussis. Not all virulence factors are protective antigens.

Robbins JB, Schneerson R, Bryla DA, Trollfors B, Taranger J, Lagergård T.

Adv Exp Med Biol. 1998;452:207-18. Review.

PMID:
9889975
13.

Measurement of human serum IgG antibodies or a surrogate is sufficient to standardize (predict efficacy) vaccines.

Robbins JB, Schneerson R, Szu SC, Bryla DA, Lin FY.

Dev Biol Stand. 1998;95:221-2. No abstract available.

PMID:
9855435
14.

Standardization may suffice for licensure of conjugate vaccines.

Robbins JB, Schneerson R, Szu SC, Bryla DA, Lin FY, Gotschlich EC.

Dev Biol Stand. 1998;95:161-7. Review.

PMID:
9855427
15.

Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers.

Gupta RK, Taylor DN, Bryla DA, Robbins JB, Szu SC.

Infect Immun. 1998 Jul;66(7):3095-9.

16.

Immunization of children with pertussis toxoid decreases spread of pertussis within the family.

Trollfors B, Taranger J, Lagergård T, Sundh V, Bryla DA, Schneerson R, Robbins JB.

Pediatr Infect Dis J. 1998 Mar;17(3):196-9.

PMID:
9535245
17.
18.

Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker.

Kossaczka Z, Bystricky S, Bryla DA, Shiloach J, Robbins JB, Szu SC.

Infect Immun. 1997 Jun;65(6):2088-93.

19.

Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis.

Trollfors B, Taranger J, Lagergård T, Lind L, Sundh V, Zackrisson G, Bryla DA, Robbins JB.

J Pediatr. 1997 Apr;130(4):532-6.

PMID:
9108848
20.

Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants.

Taranger J, Trollfors B, Lagergård T, Lind L, Sundh V, Zackrisson G, Bryla DA, Robbins JB.

Pediatr Infect Dis J. 1997 Feb;16(2):180-4.

PMID:
9041597
22.

Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis.

Welch PG, Fattom A, Moore J Jr, Schneerson R, Shiloach J, Bryla DA, Li X, Robbins JB.

J Am Soc Nephrol. 1996 Feb;7(2):247-53.

24.

Prevention of systemic infections caused by group B streptococcus and Staphylococcus aureus by multivalent polysaccharide-protein conjugate vaccines.

Robbins JB, Schneerson R, Vann WF, Bryla DA, Fattom A.

Ann N Y Acad Sci. 1995 May 31;754:68-82. Review. No abstract available.

PMID:
7625682
25.
26.

Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.

Szu SC, Taylor DN, Trofa AC, Clements JD, Shiloach J, Sadoff JC, Bryla DA, Robbins JB.

Infect Immun. 1994 Oct;62(10):4440-4.

27.

Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A.

Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, Li X, Shiloach J, Bryla DA, Robbins JB.

Infect Immun. 1993 Mar;61(3):1023-32.

28.

Intelligence at six years in relation to neonatal bilirubin levels: follow-up of the National Institute of Child Health and Human Development Clinical Trial of Phototherapy.

Scheidt PC, Graubard BI, Nelson KB, Hirtz DG, Hoffman HJ, Gartner LM, Bryla DA.

Pediatrics. 1991 Jun;87(6):797-805.

PMID:
2034482
29.
30.

Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report.

Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M, Schulz D, Armand J, Bryla DA, Trollfors B, et al.

N Engl J Med. 1987 Oct 29;317(18):1101-4.

PMID:
3657877
31.

Phototherapy and patent ductus arteriosus.

Scheidt PC, Bryla DA, Hoffman HJ.

Pediatrics. 1987 Oct;80(4):593-4. No abstract available.

PMID:
3658579
32.

Phototherapy for hyperbilirubinemia of hemolytic disease of the newborn.

Maurer HM, Kirkpatrick BV, McWilliams NB, Draper DA, Bryla DA.

Pediatrics. 1985 Feb;75(2 Pt 2):407-12. No abstract available.

PMID:
4038554
33.

Photodosimeter badge system.

Scheidt PC, Sternthal PM, Anderson R, Studholme R, Bryla DA, Fetterly KL.

Pediatrics. 1985 Feb;75(2 Pt 2):437-9. No abstract available.

PMID:
3969355
34.

Metabolic aspects of phototherapy.

Wu PY, Hodgman JE, Kirkpatrick BV, White NB Jr, Bryla DA.

Pediatrics. 1985 Feb;75(2 Pt 2):427-33. No abstract available.

PMID:
3969353
35.

Neonatal and infant mortality in relation to phototherapy.

Lipsitz PJ, Gartner LM, Bryla DA.

Pediatrics. 1985 Feb;75(2 Pt 2):422-6. No abstract available.

PMID:
3969352
36.

Morbidity and mortality associated with exchange transfusion.

Keenan WJ, Novak KK, Sutherland JM, Bryla DA, Fetterly KL.

Pediatrics. 1985 Feb;75(2 Pt 2):417-21. No abstract available.

PMID:
3969351
37.

Comparison of phototherapy results in small-for-gestational-age and appropriate-for-gestational-age infants weighing less than 2,000 grams.

Hodgman JE, Wu PY, White NB Jr, Bryla DA.

Pediatrics. 1985 Feb;75(2 Pt 2):413-6. No abstract available.

PMID:
3969350
38.

Effect of phototherapy on albumin binding of bilirubin.

Gartner LM, Lee KS, Keenan WJ, White NB Jr, Bryla DA.

Pediatrics. 1985 Feb;75(2 Pt 2):401-6. No abstract available.

PMID:
3969349
39.

Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia.

Brown AK, Kim MH, Wu PY, Bryla DA.

Pediatrics. 1985 Feb;75(2 Pt 2):393-400. No abstract available.

PMID:
3881731
40.
41.

One-year follow-up of infants exposed to ultrasound in utero.

Scheidt PC, Stanley F, Bryla DA.

Am J Obstet Gynecol. 1978 Aug 1;131(7):743-8.

PMID:
686067

Supplemental Content

Loading ...
Support Center